Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Oncology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022 Professor Krzysztof Krzemieniecki Award

open access

Vol 14, No 3 (2018)
Review paper
Published online: 2018-06-20
View PDF Download PDF file
Get Citation

Management of patients with metastatic castration-resistant prostate cancer — second-line treatment options according to the Polish National Health Found therapeutic program

Wojciech Rogowski1, Łukasz Grzęda1, Jakub Żołnierek1
DOI: 10.5603/OCP.2018.0017
·
Oncol Clin Pract 2018;14(3):148-155.
Affiliations
  1. Oddział Onkologii Klinicznej, Magodent Sp. z o.o. Warszawa

open access

Vol 14, No 3 (2018)
REVIEW ARTICLES
Published online: 2018-06-20

Abstract

Prostate cancer is one of the most common malignancies among men worldwide. According to ESMO recommendations, systemic treatment of castrate-resistant prostate cancer (CRPC) patients includes hormonal treatment, radionuclides, and immunotherapy, and the choice of appropriate method depends, among others, on clinical symptoms of disease and possible presence of distant metastases. Polish recommendations regarding systemic treatment of CRPC are different, mainly due to distinct reimbursement conditions for individual drugs. The purpose of the two subsequent publications is to present the options of systemic treatment for CRPC patients within the Polish National Health Fund drug program. The first of the articles presents second-line treatment.

Abstract

Prostate cancer is one of the most common malignancies among men worldwide. According to ESMO recommendations, systemic treatment of castrate-resistant prostate cancer (CRPC) patients includes hormonal treatment, radionuclides, and immunotherapy, and the choice of appropriate method depends, among others, on clinical symptoms of disease and possible presence of distant metastases. Polish recommendations regarding systemic treatment of CRPC are different, mainly due to distinct reimbursement conditions for individual drugs. The purpose of the two subsequent publications is to present the options of systemic treatment for CRPC patients within the Polish National Health Fund drug program. The first of the articles presents second-line treatment.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

prostate cancer; castration-resistant prostate cancer; systemic treatment; second line setting

About this article
Title

Management of patients with metastatic castration-resistant prostate cancer — second-line treatment options according to the Polish National Health Found therapeutic program

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 3 (2018)

Article type

Review paper

Pages

148-155

Published online

2018-06-20

Page views

334

Article views/downloads

440

DOI

10.5603/OCP.2018.0017

Bibliographic record

Oncol Clin Pract 2018;14(3):148-155.

Keywords

prostate cancer
castration-resistant prostate cancer
systemic treatment
second line setting

Authors

Wojciech Rogowski
Łukasz Grzęda
Jakub Żołnierek

References (15)
  1. Wysocki PJ, Borkowski T. Nowotwory układu moczowo-płciowego. W: M. Krzakowski, P. Potemski, K. Warzocha, P. Wysocki (red.). Onkologia kliniczna. Via Medica, Gdańsk 2015.
  2. Krajowy rejestr nowotworów, http://onkologia.org.pl.
  3. Didkowska J. Epidemiologia nowotworów układu moczowo-płciowego w Polsce. W: E. Senkus-Konefka, R. Zdrojowy (red.). Nowotwory układu moczowo-połciowego. Via Medica, Gdańsk 2013.
  4. Wysocki P. Miejsce octanu abirateronu w leczeniu chorych na przerzutowego raka gruczołu krokowego. Onkol. Prakt. Klin. – Edukacja. 2017; 3: 247–251.
  5. Wysocki P. Enzalutamid — nowy lek w leczeniu raka gruczołu krokowego opornego na kastrację. Onkol Prakt Klin. 2013; 9: 186–190.
  6. Gołąbek T, Chłosta PL. Podsumowanie opartych na dowodach zaleceń panelu ekspertów dotyczących deprywacji androgenowej w leczeniu miejscowego i zaawansowanego raka gruczołu krokowego. Przegl Urol. 2016; 99: 30–33.
  7. Parker C, Gillessen S, Heidenreich A, et al. ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v69–v77.
    CrossRefPubMed
  8. Itrych B. Terapia hormonalna chorych na raka gruczołu krokowego — deprywacja androgenowa. Onkol. po Dypl. z Hemat. 2017; 2: 23–26.
  9. Borówka A, Fijuth J, Potemski P. Rak gruczołu krokowego. W: M. Krzakowski, K. Warzocha (red.). Zalecenia postepowania diagnostyczno-terapeutycznego w nowotworach złośliwych — 2013 rok. Via Medica, Gdańsk 2013.
  10. ZYTIGATM — Charakterystyka produktu leczniczego, 2017, https://ec.europa.eu/health/documents/community-register/2016/20161109136263/anx_136263_pl.pdf.
  11. Itrych B. Rak gruczołu krokowego oporny na kastrację — obecne możliwości leczenia w ramach programu lekowego NFZ. Onkol. po Dypl. z Hemat. 2017; 14: 36–43.
  12. ICD-10 C61, Załącznik B.56. Leczenie opornego na kastrację raka gruczołu krokowego, http://www.mz.gov.pl/leki/refundacja/programy-lekowe.
  13. XtandiTM — Charakterystyka produktu leczniczego, 2017, https://ec.europa.eu/health/documents/community-register/2016/20161212136636/anx_136636_pl.pdf.
  14. Parker C, Nilsson S, Heinrich D, et al. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3): 213–223.
    CrossRefPubMed
  15. de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147–1154.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl